Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eloralintide in Obesity/Overweight, Type 2 Diabetes, and Increased CV Risk
NCT07900633Phase 3Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2026
- Primary completion
- Nov 2029
- Countries
- 21
01
Overview
A Phase 3 trial of eloralintide in obesity, type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
eloralintide
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07900633.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07900633.